GlassScriptPhysician profile
Matthew K Park
NPI 1437114451
$2,638.31
in general payments reported to CMS, 2019-2025
18 companies · $342 in 2025
The $342 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $774 · 2020: $674 · 2021: $371 · 2023: $476 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $738 · Food and Beverage: $79.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $738.39 |
| Food and Beverage | $79.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $793.39 | 2023-2025 | Single Use Suction Valve (Sterile), Olympus |
| Astrazeneca Pharmaceuticals LP | $511.14 | 2019-2021 | |
| Glaxosmithkline, LLC. | $452.74 | 2019-2025 | Nucala |
| Insmed, INC. | $191.29 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.91 | 2019-2021 | |
| Grifols USA, LLC | $125.60 | 2019-2020 | |
| Veran Medical Technologies, INC. | $104.04 | 2020 | |
| Genentech USA, INC. | $69.09 | 2019 | |
| Genzyme Corporation | $47.62 | 2019-2021 | |
| Biomerieux INC | $26.74 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $23.10 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $22.44 | 2019 | |
| Gilead Sciences, INC. | $22.02 | 2021 | |
| Sunovion Pharmaceuticals INC. | $21.50 | 2019 | |
| Allergan, INC. | $20.02 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $14.92 | 2019 | |
| Inogen, INC. | $13.00 | 2019 | |
| Aytu Biopharma, INC. | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.